background: nonalcoholic steatohepatitis (nash) is part of a broad spectrum of nonalcoholic fatty liver diseases that can lead to cirrhosis. to date, there is no effective medical treatment for nash. we aim to compare the effect of aerobic exercise in conjunction with diet to diet alone on the improvement of metabolic syndrome and insulin resistance in patients with nash. materials and methods:...

non-alcoholic steatohepatitis (nash) is a disease of unknown origin characterized histologically by alcoholic-like liver injury in the absence in the absence of significant alcohol intake. this study was conducted to assess the clinical and pathological features of nash patients in iran. patients with elevated liver transaminases, negative serologic markers of viral or autoimmune hepatitis and ...

no abstract

a Unidad de Hepatología, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, España b Unitat de Suport a la Recerca (USR) Metropolitana Nord, Institut d’Investigació en Atenció Primaria (IDIAP) Jordi Gol, Centro de Investigación en Red de Enfermedades Hepáticas y Digesti...

Surrogate endpoints for clinical proof of concept (POC) trials in nonalcoholic steatohepatitis (NASH) are based upon expert pathological review of liver biopsies. During early development, these long-term POC studies (≥48 weeks) add cost and time to the "Go/No Go" decision process. However, it is possible to conduct short-term noninvasive POC studies utilizing biomarkers and magnetic resonance ...

Many animal models of nonalcoholic steatohepatitis have been reported. While these models exhibit mild onset of hepatitis and fibrosis, induction is often slow. For faster screening of drug candidates, there is a compelling need for convenient animal models of steatohepatitis and nonalcoholic steatohepatitis in which fatty liver and hepatitis are stably induced within a short period. Here, we a...

Nonalcoholic fatty liver disease (NAFLD) consists of a broad spectrum of liver lesions ranging from fatty liver (FL), through nonalcoholic steatohepatitis (NASH), up to cirrhosis. The incidence of nonalcoholic fatty liver disease has increased in recent years due to the high rate of obesity in developed countries. Although the dogma "simple steatosis - benign prognosis, nonalcoholic steatohepat...

conclusions elevated serum pth level was the predictive factor for nash in morbidly obese patients. also, we reported elevated serum liver enzymes, high serum pth levels and older age as predictors of nash in patients seeking obesity surgical treatments. results forty-six patients (34 women, aged 36.5 ± 10.6 years) were analyzed. the mean levels of liver enzymes were significantly higher in the...

No abstract

INTRODUCTION Nonalcoholic steatohepatitis (NASH), a subset of nonalcoholic fatty liver disease (NAFLD), is becoming an increasing health concern, with current data showing the prevalence in the United States to range between 5.7%–16.5% (1,2). Patients with NASH lack a history of significant alcohol consumption, but liver biopsy findings are almost identical to biopsy findings in patients with a...